User menu

Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.

Bibliographic reference Sternberg, Cora N ; Baskin-Bey, Edwina S ; Watson, Mark ; Worsfold, Andrew ; Rider, Alex ; et. al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.. In: BMC Urology, Vol. 13, no.1, p. 58 (2013)
Permanent URL
  1. Ferlay J., Parkin D.M., Steliarova-Foucher E., Estimates of cancer incidence and mortality in Europe in 2008, 10.1016/j.ejca.2009.12.014
  2. CancerStats Prostate Cancer Incidence Statistics. . Accessed Oct 2012
  3. Akaza Hideyuki, Combined androgen blockade for prostate cancer: Review of efficacy, safety and cost-effectiveness, 10.1111/j.1349-7006.2010.01774.x
  4. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Van der Kwast TH, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. . Accessed Oct 2012
  5. Mottet Nicolas, Bellmunt Joaquim, Bolla Michel, Joniau Steven, Mason Malcolm, Matveev Vsevolod, Schmid Hans-Peter, Van der Kwast Theo, Wiegel Thomas, Zattoni Filiberto, Heidenreich Axel, EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, 10.1016/j.eururo.2011.01.025
  6. Seruga B, Tannock IF: The changing face of hormonal therapy for prostate cancer. Ann Oncol. 2008, 19 (Suppl 7): vii79-vii85.
  7. Anderson P., Benford M., Harris N., Karavali M., Piercy J., Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand, 10.1185/03007990802457040
  8. Brédart Anne, Dolbeault Sylvie, Savignoni Alexia, Simard Sébastien, Gomme Stéphanie, Asselain Bernard, Copel Laure, Pilot evaluation of a French interdisciplinary supportive care department, 10.1007/s00520-009-0617-3
  9. KOJIMA SATOKO, SUZUKI HIROYOSHI, AKAKURA KOICHIRO, SHIMBO MASAKI, ICHIKAWA TOMOHIKO, ITO HARUO, Alternative Antiandrogens to Treat Prostate Cancer Relapse After Initial Hormone Therapy, 10.1097/01.ju.0000106190.32540.6c
  10. Lawrentschuk Nathan, Fernandes Kimberly, Bell David, Barkin Jack, Fleshner Neil, Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence, 10.1016/j.juro.2010.10.055
  11. Scher Howard I., Steineck Gunnar, Kevin Kelly William, Hormone-refractory (D3) prostate cancer: Refining the concept, 10.1016/s0090-4295(99)80182-4
  12. Small Eric J., Ryan Charles J., The Case for Secondary Hormonal Therapies in the Chemotherapy Age, 10.1016/j.juro.2006.06.071
  13. Sternberg CN, Fizazi K: The relevance of continued medical castration for patients with castration-resistant prostate cancer. AoU. 2011, 2: 34-39.
  14. Anderson John, Abrahamsson Per-Anders, Crawford David, Miller Kurt, Tombal Bertrand, Management of advanced prostate cancer: can we improve on androgen deprivation therapy?, 10.1111/j.1464-410x.2008.07590.x
  15. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R, Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome., 10.1200/jco.1988.6.9.1456
  16. Taylor C D, Elson P, Trump D L, Importance of continued testicular suppression in hormone-refractory prostate cancer., 10.1200/jco.1993.11.11.2167